Soluble Guanylate Cyclase: a New Therapeutic Target for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2015 Feb 12

PMID 25670386

Citations 44

Authors

A Dasgupta

L Bowman

C L DArsigny

S L Archer

Affiliations

Soon will be listed here.

Abstract

Nitric oxide (NO) activates soluble guanylate cyclase (sGC) by binding its prosthetic heme group, thereby catalyzing cyclic guanosine monophosphate (cGMP) synthesis. cGMP causes vasodilation and may inhibit smooth muscle cell proliferation and platelet aggregation. The NO-sGC-cGMP pathway is disordered in pulmonary arterial hypertension (PAH), a syndrome in which pulmonary vascular obstruction, inflammation, thrombosis, and constriction ultimately lead to death from right heart failure. Expression of sGC is increased in PAH but its function is reduced by decreased NO bioavailability, sGC oxidation and the related loss of sGC's heme group. Two classes of sGC modulators offer promise in PAH. sGC stimulators (e.g., riociguat) require heme-containing sGC to catalyze cGMP production, whereas sGC activators (e.g., cinaciguat) activate heme-free sGC. Riociguat is approved for PAH and yields functional and hemodynamic benefits similar to other therapies. Its main serious adverse effect is dose-dependent hypotension. Riociguat is also approved for inoperable chronic thromboembolic pulmonary hypertension.

Citing Articles

Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.

Corboz M, Nguyen T, Stautberg A, Cipolla D, Perkins W, Chapman R J Aerosol Med Pulm Drug Deliv. 2024; 37(5):241-283.

PMID: 39388691 PMC: 11502635. DOI: 10.1089/jamp.2024.0016.

Kidney Dysfunction, Hepatic Impairment, and Lipid Metabolism Abnormalities in Patients with Precapillary Pulmonary Hypertension.

Iancu D, Varga A, Cristescu L, Dumbrava R, Stoica F, Moldovan D Diagnostics (Basel). 2024; 14(16).

PMID: 39202312 PMC: 11353558. DOI: 10.3390/diagnostics14161824.

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again.

Bahi M, Li C, Wang G, Korman B Int J Mol Sci. 2024; 25(9).

PMID: 38731946 PMC: 11084945. DOI: 10.3390/ijms25094728.

Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.

Abuelazm M, Attia A, Abdelnabi M, Jafar U, Almaadawy O, Elzeftawy M Egypt Heart J. 2024; 76(1):6.

PMID: 38265696 PMC: 10808080. DOI: 10.1186/s43044-024-00437-x.

Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases.

Yin Q, Zheng X, Song Y, Wu L, Li L, Tong R Front Pharmacol. 2024; 14:1272073.

PMID: 38186653 PMC: 10771398. DOI: 10.3389/fphar.2023.1272073.

References

Schwappacher R, Kilic A, Kojonazarov B, Lang M, Diep T, Zhuang S . A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension. J Biol Chem. 2013; 288(23):16557-16566. PMC: 3675591. DOI: 10.1074/jbc.M113.458729. View

Kielstein J, Bode-Boger S, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D . Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2005; 25(7):1414-8. DOI: 10.1161/01.ATV.0000168414.06853.f0. View

Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G . Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol. 2008; 295(4):H1763-71. DOI: 10.1152/ajpheart.51.2008. View

Wunder F, Stasch J, Hutter J, Alonso-Alija C, Huser J, Lohrmann E . A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal Biochem. 2005; 339(1):104-12. DOI: 10.1016/j.ab.2004.12.025. View

Cary S, Winger J, Derbyshire E, Marletta M . Nitric oxide signaling: no longer simply on or off. Trends Biochem Sci. 2006; 31(4):231-9. DOI: 10.1016/j.tibs.2006.02.003. View

Selwood D, Brummell D, Budworth J, Burtin G, CAMPBELL R, Chana S . Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem. 2001; 44(1):78-93. DOI: 10.1021/jm001034k. View

Meurer S, Pioch S, Pabst T, Opitz N, Schmidt P, Beckhaus T . Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res. 2009; 105(1):33-41. DOI: 10.1161/CIRCRESAHA.109.198234. View

Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T . Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2011; 301(5):L755-64. PMC: 3213988. DOI: 10.1152/ajplung.00138.2010. View

Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C . Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014; 146(5):1274-1285. PMC: 4219342. DOI: 10.1378/chest.14-0106. View

10.

Miller L, Nakane M, Hsieh G, Chang R, Kolasa T, Moreland R . A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. 2002; 72(9):1015-25. DOI: 10.1016/s0024-3205(02)02361-5. View

11.

Methner C, Buonincontri G, Hu C, Vujic A, Kretschmer A, Sawiak S . Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging. PLoS One. 2014; 8(12):e83910. PMC: 3877128. DOI: 10.1371/journal.pone.0083910. View

12.

Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M . Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem. 2009; 4(5):853-65. DOI: 10.1002/cmdc.200900014. View

13.

Roy B, Mo E, Vernon J, Garthwaite J . Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol. 2008; 153(7):1495-504. PMC: 2437902. DOI: 10.1038/sj.bjp.0707687. View

14.

Martin E, Berka V, Sharina I, Tsai A . Mechanism of binding of NO to soluble guanylyl cyclase: implication for the second NO binding to the heme proximal site. Biochemistry. 2012; 51(13):2737-46. PMC: 3319481. DOI: 10.1021/bi300105s. View

15.

Ghofrani H, Galie N, Grimminger F, Grunig E, Humbert M, Jing Z . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):330-40. DOI: 10.1056/NEJMoa1209655. View

16.

Radovits T, Korkmaz S, Miesel-Groschel C, Seidel B, Stasch J, Merkely B . Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg. 2010; 39(2):248-55. DOI: 10.1016/j.ejcts.2010.05.025. View

17.

Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T . Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension. 2011; 59(2):248-55. PMC: 3272453. DOI: 10.1161/HYPERTENSIONAHA.111.181990. View

18.

Strange G, Keogh A, Dalton B, Gabbay E . Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. Expert Rev Pharmacoecon Outcomes Res. 2011; 11(3):253-63. DOI: 10.1586/erp.11.26. View

19.

Evgenov O, Kohane D, Bloch K, Stasch J, Volpato G, Bellas E . Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med. 2007; 176(11):1138-45. PMC: 2176100. DOI: 10.1164/rccm.200707-1121OC. View

20.

Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann L, Wellkisch K . Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens. 2010; 28(8):1666-75. DOI: 10.1097/HJH.0b013e32833b558c. View